FWM
AXSM icon

Focused Wealth Management’s Axsome Therapeutics AXSM Stock Holding History

Focused Wealth Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-3,000
Closed -$2K – 696
2019
Q2 		$2K Buy
+3,000
New +$60.1K ﹤0.01% 658

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Focused Wealth Management's AXSM Position: Q4 2019 in Review

Focused Wealth Management sold out of Axsome Therapeutics (AXSM) in Q4 2019, closing a stake of 1,050 shares — an estimated $21K sold.

Focused Wealth Management first reported a position in AXSM in Q1 2019 and held it in 2 quarters. The position peaked at $64K in Q1 2019. 169 funds tracked by Wall St. Rank hold AXSM as of Q4 2019.

  • Focused Wealth Management reported no remaining Axsome Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Focused Wealth Management sold 1,050 Axsome Therapeutics shares in Q4 2019, an estimated $21K.
  • Focused Wealth Management first reported a position in Axsome Therapeutics in Q1 2019 and held it in 2 quarters.
  • Focused Wealth Management's Axsome Therapeutics position peaked at $64K in Q1 2019.
  • 169 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2019.

Based on Focused Wealth Management's 13F filing for Q4 2019, filed 21 Jan 2020.